Clinical Trial Update: An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

View source ↗

Summary

An observational trial of Rituximab (MabThera/Rituxan) in relapsing or refractory chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• MabThera/Rituxan (Rituximab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphocytic Leukemia, Chronic | Status: COMPLETED